Dr. Fiehn has received consulting fees, speaking fees, and/or honoraria from Medac (less than $10,000).
The future of folic acid antagonist therapy in rheumatoid arthritis
Article first published online: 30 DEC 2008
Copyright © 2008 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 60, Issue 1, pages 1–4, January 2009
How to Cite
Fiehn, C. (2009), The future of folic acid antagonist therapy in rheumatoid arthritis. Arthritis & Rheumatism, 60: 1–4. doi: 10.1002/art.24216
- Issue published online: 30 DEC 2008
- Article first published online: 30 DEC 2008
- Manuscript Accepted: 3 OCT 2008
- Manuscript Received: 26 AUG 2008
- 2PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26–37., , , , , , et al, for the
- 5Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004; 50: 2766–74., , , , , , et al.
- 8MC-MTX.6/RH Study Group. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008; 58: 73–81., , , , , , et al, for the